Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade.
Paul Oberstein, MD
Advertisement
Articles by Paul Oberstein, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
Weighing Bispecific Antibodies Against CAR T-Cell Therapy in Follicular Lymphoma
3
Talazoparib/Enzalutamide sNDA Receives FDA Priority Review in HRR+ CSPC
4
Bridging CAR T-Cell and Bispecific Therapy Access in Community Oncology
5